Radiation oncology had another active week on LinkedIn, with posts moving across education, global meetings, new technologies, patient-centered care, and clinical research.
From PTCOG 2026 discussions on particle therapy and tumor biology to Korean Cancer Association insights on implementation and efficiency, from online adaptive radiotherapy and AI-driven workflows to WRAD advocacy, low-dose radiotherapy, salvage HDR brachytherapy, and new bone metastases resources, the field continues to show how broad and fast-moving it really is.
Here are the radiation oncology posts worth catching up on this week.
Manya Betageri – Full Professor I Clinical Coordinator for Bellevue College Radiation Therapy / Radiation Therapy Educator / Board (ARRT) Certified/Registered Radiation Therapist / HCPC, UK Certified/Registered Therapeutic Radiographer
Bellevue College Commencement 2026. Congratulations to the Radiation Therapy Class of 2026 and the Dosimetry Class of 2026
Andreia Maia Oliveira – Medical Physicist at Universität Bern
It was a pleasure to attend the Annual Conference of the Particle Therapy Cooperative Group (PTCOG) 2026 in Deauville, France.
A special thank you to my supervisor, Arturs Meijers and PSI Paul Scherrer Institut, for making this opportunity possible.The meeting was an excellent opportunity to connect with colleagues from across the world, exchange ideas and discuss the future of particle therapy. I also had the chance to connect with my colleagues from MedAustron, which made the experience even more meaningful. Meeting my Portuguese professor, Luís Cunha, whom I have known for 10 years, as well as oncologist Dr. Sofia from Instituto Português de Oncologia do Porto (IPO-Porto), and having interesting discussions.
The educational sessions provided a fascinating journey from Periodic QA to the emerging era of adaptive particle therapy.
One of the highlights was the visit to CYCLHAD, one of the few particle therapy centers in Europe, located in Normandy. This impressive facility brings together cutting-edge technology and research to advance multi-particle cancer therapy.
Had the chance to speak with people from the industry and to try the upright position from Leo Cancer Care, which has already started to be used to treat pediatric and adult patients, and to learn more about what RaySearch Laboratories is preparing for upcoming versions of its treatment planning and workflow platforms.
Another memorable experience was observing how the clinical team at the François Baclesse Center treats pediatric patients without general anesthesia through creative, non-invasive distraction techniques. Seeing children actively engaged in play and taking on the role of radiation therapists was both innovative and heartwarming, demonstrating how patient-centered care can transform the treatment experience.
The scientific program was outstanding. Among many excellent presentations, I particularly enjoyed the lecture by Nobel Prize winner Alain Aspect, which offered remarkable insights into the impact of fundamental physics on modern technologies.
See presentations about my niche of work, ocular proton therapy, which explore its clinical applications, emerging approaches to precision targeting and patient positioning.
I was also honored to co-chair the session “Physics: Treatment Planning Algorithms” together with Suresh Rana, PhD. The session generated engaging discussions, including perspectives on the evaluation of dirty dose.
The conference concluded with a lively balloon debate on how particle therapy can achieve a greater role in radiation oncology. The scientific community voted in favor of the statement:
“Let tumor biology drive the selection of beam quality.”Thank you to the organizers, speakers, and participants for an inspiring meeting filled with learning, collaboration, and new ideas. Looking forward to continuing these discussions and seeing how our field evolves in the coming years.
Peter van Rossum – MD, PhD | Radiation oncologist | Epidemiologist at Amsterdam UMC
Two days in #Seoul, countless lessons to bring home!🇰🇷
Beyond the outstanding science at the Korean Cancer Association (KCA) 2026 meeting, my biggest takeaways from visiting were:
#Efficiency: departments treating astonishing numbers of patients by optimally supporting physicians (5x more patients per doctor). With growing workforce shortages, there is much we can learn from this model.
#Implementation: seeing the Amsterdam UMC – Radiotherapie NIMV technique already broadly implemented for lung and liver #SBRT at Yonsei University Health System by Dr. Jee Suk Chang. Less bureaucracy, faster delivery of innovative patient care.
#Hospitality: truly on another level. Warm, generous, and unforgettable. A very special thank you to Dr. Jee Suk Chang, for your personal kindness and guiding me through the city and your impressive hospital.I was also delighted to speak on OMEC – OligoMetastasis in Esophago-gastric Cancer, kindly invited by Prof. Yong Chan Ahn. A wonderful faculty dinner in a historic royal residence with Prof. Eui Kyu Chie and others was another highlight.
Finally, I am excited that Prof. Sun Young Rha will soon open the Yonsei site for our international #OMEC-5 #trial.
Thank you all for the inspiring discussions, warm welcome, new friendships, and future #collaborations. 🇰🇷🇳🇱
Lohith Reddy – Consultant Radiation Oncologist at HCG
Something big is coming to Online adaptive radiotherapy.
Honoured to be invited as a Key Opinion Leader by United Imaging for what I genuinely believe is about to reset the benchmark in the RT space.
Here’s the thing I keep telling my team: we are watching radiation oncology compress a decade of progress into a couple of years. Auto-contouring that used to be a “nice assist” is now operating at a level that makes you stop and stare. AI isn’t bolting onto the workflow anymore — it’s becoming the workflow. Adaptive, online, real-time, anatomy-aware. The machine is finally keeping pace with the biology.
What excites me isn’t the hardware alone. It’s what it unlocks:
→ Contouring that’s faster and more consistent than a busy practising radiation oncologist.
→ Plan adaptation that responds to the patient who showed up today, not the patient we scanned 2-3 daya ago.
→ A path to precision that scales — across centres, across geographies, across the patients who never had access before.As someone living at the intersection of AI, radiomics and immuno-RT every single day, I can tell you: this is the augmentation we’ve been waiting for. Not AI replacing the oncologist. AI making the oncologist superhuman.
Melvin L.K. Chua – Head of Department of Head Neck & Thoracic Cancers at National Cancer Centre Singapore
What a week!!!
Grateful to American Society of Clinical Oncology (ASCO) for the opportunity to be part of the Program Chair committee since 2022, shaping the #Breakthrough meeting in #Asia #APAC I had learnt so much from Lillian Siu , colleagues, ASCO staffs who taught me so much about what it takes to build a rich meeting program and a successful event!
When it was decided that the meeting was coming to 🇸🇬 there was some apprehension how it will turn out, but WOW!!! The support and turnout surpassed all expectations!
It is so nice to see the cross exchanges between faculties and trainees, and there was actual mixing between the community and industry partners.
It takes a village to start a movement and I end this week with my heart fulfilled.
Prakash Umbarkar – Senior Radiation Therapist at P. D. Hinduja National Hospital & Medical Research Centre
Proud to Represent India at the WRAD Regional Champions Meeting
Honored to participate in the World Radiotherapy Awareness Day (WRAD) Regional Champions Meeting, joining passionate advocates from around the world with one shared vision—One Voice for Radiotherapy.The meeting focused on strengthening global collaboration, expanding radiotherapy awareness, and empowering Regional Champions to improve access to quality cancer care.
Together, we are working to reduce misconceptions, educate communities, and ensure every patient understands the life-saving value of radiotherapy.
Proud to contribute to this global movement and to represent India in advancing radiotherapy advocacy.
Together, we can create awareness, inspire action, and improve access to radiotherapy for all.
Bobby Koneru – Chief of Radiation Medicine @ MercyOne Dubuque and MercyHealth FHN | Asst Prof @ Loyola University | Founder and President, Paramount Oncology Group (POG) | Co-Founder and CMO of JointGlow | Industry KOL
I spent time with a Legend today.
Had the absolute honor of sitting down with Dr. Luga Podesta in Naples…a true icon in sports medicine. World-class athletes. Grammy-winning musicians. Elite performers from every corner of the globe. They all find their way to this man.
And today, we talked about something that could change the game for ALL of them — Low Dose Radiotherapy.
The future of musculoskeletal care isn’t just coming. It’s already here. And the best minds in medicine are paying attention.
Patricia Willisch – Radiation Oncologist from Vigo, Spain
Thrilled to share our new publication:
“Magnetic resonance imaging-guided salvage high-dose-rate brachytherapy for local recurrence after prostatectomy and external beam radiotherapy.”This study reports one of the longest follow-up series available for salvage HDR brachytherapy in patients with local recurrence after radical prostatectomy and previous external beam radiotherapy.
Key findings:
17 patients treated between 2015 and 2024.
Median follow-up of 74 months.
64.7% local control within the treated region at 6 years.
5-year biochemical recurrence-free survival of 62.7%.
5-year metastasis-free survival of 81.9%.
5-year overall survival of 86.7%.
No patients received systematic ADT at the time of salvage HDR brachytherapy.
Grade ≥3 genitourinary toxicity of 5.9%, with no severe gastrointestinal toxicity.These results support MRI-guided salvage HDR brachytherapy as a feasible and effective treatment option for selected patients with local recurrence after prostatectomy and radiotherapy, achieving durable disease control with acceptable toxicity.
Shing Fung Lee – Consultant, Radiation Oncology, at National University Cancer Institute, Singapore
A long international team effort has come together.
We are pleased to share the new Handbook of Bone Metastases, available in two versions:
One for patients and caregivers
One for healthcare professionalsThe patient handbook is written in plain language for people living with bone metastases and their carers and families. It explains common symptoms, treatment options, supportive care, possible complications, and when to seek urgent medical attention.
The healthcare professional handbook is a practical reference for clinicians, nurses, allied health professionals, and trainees. It covers the assessment and management of bone metastases, radiotherapy, systemic treatment, supportive care, spinal cord compression, multidisciplinary care, and communication with patients and families.
Our hope is that these resources can support clearer conversations, better education, and more consistent care for patients with bone metastases.
I am very grateful to my fellow editors, Joel A. Finkelstein and Henry Wong, and to all the international contributors who generously shared their time, expertise, and perspectives. Jessie PL Yip Bala Vellayappan Timothy Cheo Mike Chao Raymond Chan Tee Lim Gustavo Nader Marta Marcus Dreosti Adrian Chan Eva Oldenburger Linda Probyn Glenn Bauman
This project builds on the earlier editions and the long-standing collaborative work in bone metastases care. Both books are freely available. Please share them with patients, caregivers, colleagues, cancer centres, patient advocacy groups, and training programmes where they may be useful.
Christelle Bouchart – Associate Professor Radiation-Oncology at F.R.S. – FNRS
Real joy to participate to this Annual joint Meeting EPC/IAP in Istanbul, many wonderful encounters and a beautiful city. See you all in London in July!
Pancreatic Cancer Europe
F.R.S. – FNRS
Association Jules Bordet
Institut Jules Bordet
Hôpital Universitaire de Bruxelles (H.U.B) – Academisch Ziekenhuis Brussel (H.U.B)